Zoster Vaccine Live

BIOLOGICAL4 trials

Sponsors

Merck Sharp & Dohme LLC, Rockefeller University, University of Washington

Conditions

Hepatitis CHerpes ZosterShingles

Phase 3

Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)

CompletedNCT01527370

Merck Sharp & Dohme LLCHerpes Zoster, Shingles

Start: 2012-10-31End: 2013-04-09Updated: 2018-09-18

Phase 4

ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)

CompletedNCT01556451

Merck Sharp & Dohme LLCHerpes Zoster, Shingles

Start: 2012-04-30End: 2012-10-31Updated: 2017-04-12

Immune Response to Shingles Vaccination

CompletedNCT02624375

University of WashingtonShingles

Start: 2016-02-29End: 2019-11-30Updated: 2019-12-05

Unknown Phase

Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination

TerminatedNCT02590068

Rockefeller UniversityHepatitis C

Start: 2015-12-31End: 2017-09-08Updated: 2019-12-18

Related Papers

Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults

Journal of Korean Medical Science2016-01-018 citations